Variables | Male BRCAm carriers (n = 294) | Female BRCAm carriers (n = 349) | Male non-BRCAm carriers (n = 4577) | P* | P# |
---|---|---|---|---|---|
Incidence of BRCA1/2 mutation | |||||
 carrier | 294 (6.0) | 349 (6.6) | – | 0.275 | – |
 non-carrier | 4577 (94.0) | 4969 (93.4) |  |  |  |
Race | |||||
 white | 225 (76.5) | 246 (70.5) | 3238 (70.7) | 0.001 | 0.316 |
 Asian | 19 (6.5) | 21 (6.0) | 337 (7.4) |  |  |
 Black/African American | 12 (4.1) | 46 (13.2) | 274 (6.0) |  |  |
 other | 0(0.0) | 3 (0.9) | 9 (0.2) |  |  |
 unknown | 38 (12.9) | 33 (9.5) | 719 (15.7) |  |  |
Age at diagnosis | |||||
 < 40 | 14 (4.8) | 27 (7.7) | 454 (9.9) | 0.15 | < 0.001 |
 40–49 | 28 (9.5) | 42 (12.0) | 519 (11.3) |  |  |
 50–59 | 64 (21.8) | 93 (26.6) | 1095 (23.9) |  |  |
 60–69 | 81 (27.6) | 91 (26.1) | 1388 (30.3) |  |  |
 70–79 | 81 (27.6) | 68 (19.5) | 858 (18.7) |  |  |
 ≥ 80 | 24 (8.2) | 26 (7.4) | 239 (5.2) |  |  |
 unknown | 2 (0.7) | 2 (0.6) | 24 (0.5) |  |  |
Anatomic site of tumor | |||||
 lung | 57 (19.4) | 36 (10.3) | 541 (11.8) | < 0.001 | < 0.001 |
 skin | 48 (16.3) | 24 (6.9) | 228 (5.0) |  |  |
 bladder | 46 (15.6) | 11 (3.2) | 258 (5.6) |  |  |
 stomach | 35 (11.9) | 14 (4.0) | 250 (5.5) |  |  |
 head and neck | 25 (8.5) | 6 (1.7) | 360 (7.9) |  |  |
 colorectum | 24 (8.2) | 23 (6.6) | 288 (6.3) |  |  |
 kidney | 14 (4.8) | 8 (2.3) | 565 (12.3) |  |  |
 prostate | 11 (3.7) | – | 483 (10.6) |  |  |
 CNS | 8 (2.7) | 9 (2.6) | 452 (9.9) |  |  |
 esophagus | 8 (2.7) | 1 (0.3) | 148 (3.2) |  |  |
 liver | 8 (2.7) | 4 (1.1) | 243 (5.3) |  |  |
 breast | 3 (1.0) | 54 (15.5) | 9 (0.2) |  |  |
 uterus | – | 93 (26.6) | – |  |  |
 ovary | – | 30 (8.6) | – |  |  |
 cervical | – | 27 (7.7) | – |  |  |
 other | 7 (2.4) | 9 (2.6) | 752 (16.4) |  |  |
Histology | |||||
 adenocarcinoma | 86 (29.3) | 144 (41.3) | 1355 (29.6) | < 0.001 | < 0.001 |
 melanoma | 48 (16.3) | 24 (6.9) | 229 (5.0) |  |  |
 urothelial carcinoma | 46 (15.6) | 11 (3.1) | 257 (5.6) |  |  |
 squamous cell carcinoma | 66 (22.4) | 40 (11.5) | 755 (16.5) |  |  |
 IBC, NST | 3 (1.0) | 47 (13.5) | 8 (0.2) |  |  |
 serous carcinoma | – | 36 (10.3) | – |  |  |
 other | 45 (15.3) | 47 (13.5) | 1973 (43.1) |  |  |
TNM stage | |||||
 0 | 1 (0.3) | 1 (0.3) | 4 (0.1) | 0.001 | 0.007 |
 I | 55 (18.7) | 50 (14.3) | 1025 (22.4) |  |  |
 II | 86 (29.3) | 82 (23.5) | 864 (18.9) |  |  |
 III | 72 (24.5) | 40 (11.5) | 823 (18.0) |  |  |
 IV | 39 (13.3) | 8 (2.3) | 507 (11.1) |  |  |
 unknown | 41 (13.9) | 168 (48.1) | 1354 (29.6) |  |  |
BRCA1/2 mutation | |||||
 BRCA1 only | 81 (27.6) | 117 (33.5) | – | 0.001 | – |
 BRCA2 only | 193 (65.6) | 183 (52.4) |  |  |  |
 both BRCA1 and BRCA2 | 20 (6.8) | 49 (14.1) |  |  |  |
Histologic grade | |||||
 low | 8 (2.7) | 18 (5.2) | 132 (2.9) | 0.309 | 0.875 |
 moderate to high | 122 (41.5) | 170 (48.9) | 1774 (38.8) |  |  |
 unknown/unclassified | 164 (55.8) | 160 (46.0) | 2671 (58.4) |  |  |
Mutation count (median) | |||||
 all | 322 (range, 11–15,832) | 379 (range, 7–25,730) | 63(range, 1–5865) | – | – |
 with BRCA1 mutation only | 309 (range, 24–3679) | 161 (range, 8–5118) | – |  |  |
 with BRCA2 mutation only | 266 (range, 11–6369) | 340 (range, 7–12,071) | – |  |  |
 with BRCA1 & BRCA2 mutation | 2390 (range, 264–15,832) | 8234 (range, 153–25,730) | – |  |  |
Radiotherapy | |||||
 no | 215 (73.1) | 218 (62.4) | 2920 (63.8) | < 0.001 | 0.009 |
 yes | 48 (16.3) | 98 (28.1) | 1010 (22.1) |  |  |
 unknown | 31 (10.6) | 33 (9.5) | 647 (14.1) |  |  |
Neoadjuvant therapy | |||||
 no | 290 (98.6) | 348 (99.7) | 4523 (98.8) | 0.274 | 0.782 |
 yes | 4 (1.4) | 1 (0.3) | 54 (1.2) |  |  |
Tumor progression | |||||
 no | 168 (57.1) | 258 (73.9) | 2865 (62.6) | < 0.001 | 0.078 |
 yes | 125 (42.5) | 90 (25.8) | 1707 (37.3) |  |  |
 unknown | 1 (0.3) | 1 (0.3) | 5 (0.1) |  |  |
Overall survival | |||||
 alive | 172 (58.5) | 282 (80.8) | 3149 (68.8) | < 0.001 | < 0.001 |
 deceased | 121 (41.2) | 66 (18.9) | 1423 (31.1) |  |  |
 unknown | 1 (0.3) | 1 (0.3) | 5 (0.1) |  |  |